Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5981838 | 0.93 | ENPP2 (0.46) | ALDH1A1KMT2ASLC6A3MEN1FKBP1A | |
| SCHEMBL16370709 | 0.86 | ALDH1A1 (0.51) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL16370006 | 0.80 | ALDH1A1 (0.49) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL16407804 | 0.80 | ALDH1A1 (0.49) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL24347012 | 0.80 | ALDH1A1 (0.60) | ALDH1A1HCAR2KMT2AMAPK1L3MBTL1 | |
| SCHEMBL3756497 | 0.80 | ALDH1A1 (0.60) | ALDH1A1HCAR2KMT2AMAPK1L3MBTL1 | |
| SCHEMBL26813875 | 0.79 | ALDH1A1 (0.47) | ALDH1A1HCAR2KMT2AMAPK1L3MBTL1 | |
| SCHEMBL991531 | 0.78 | ALDH1A1 (0.62) | ALDH1A1HCAR2KMT2AMAPK1L3MBTL1 | |
| SCHEMBL522510 | 0.78 | ALDH1A1 (0.62) | ALDH1A1HCAR2KMT2AMAPK1L3MBTL1 | |
| SCHEMBL13553671 | 0.78 | TSHR (0.50) | ALDH1A1KMT2AL3MBTL1MEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577325-B2 | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof | SYSTIMMUNE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4595978-A1 | ANTI-CD33 ANTIBODY AND ANTI-CD33 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | SystImmune, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-120131991-A | Anti-human Claudin18.2 antibody-camptothecine drug conjugate and medical application thereof | 成都百利多特生物药业有限责任公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250115679-A1 | BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. (CN) | 2025-04-10 | — | — | US | disclosed |
| US-20250059296-A1 | BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | SYSTIMMUNE INC (US) | 2025-02-20 | — | — | US | disclosed |
| CN-114409562-B | CA4 derivative and ligand-drug conjugate thereof | 四川百利药业有限责任公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-117752813-A | anti-CD 33 antibodies and anti-CD 33 antibody-drug conjugates and uses thereof | 成都百利多特生物药业有限责任公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-116212044-A | Anti-human Trop2 antibody-camptothecin drug conjugate and medical application thereof | 成都百利多特生物药业有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-116120460-A | Bispecific antibody-camptothecins drug conjugate and medical application thereof | 成都百利多特生物药业有限责任公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2022166719-A1 | CA4 DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF | 四川百利药业有限责任公司 | 2022-08-11 | — | — | WO | disclosed |
| CN-113827736-A | Camptothecin drug with high-stability hydrophilic connecting unit and conjugate thereof | 四川百利药业有限责任公司 | 2021-12-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577325-B2 | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof | IGLV6-57, EGFR, ERBB2 | ALDH1A1 3799/4885HCAR2 2367/4885KMT2A 2519/4885 |
| US-20250115679-A1 | BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | ANTXR2, PAICS, CD38 | ALDH1A1 1919/4885HCAR2 2099/4885KMT2A 3730/4885 |
| US-20250059296-A1 | BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | ANTXR2, PAICS, CD38 | ALDH1A1 1919/4885HCAR2 2099/4885KMT2A 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.